首页 > R&D Systems > R&D Systems/Human JAM-A Antibody/MAB1103/100 ug

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Human JAM-A Antibody/MAB1103/100 ug

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

MAB1103-100ug

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Species ReactivityHumanSpecificityDetects human JAM-A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinanthuman (rh) JAM-B, recombinant mouse (rm) JAM-A, or rmJAM-4 is observed.SourceMonoclonal Mouse IgG1 Clone # 654806PurificationProtein A or G purified from hybridoma culture supernatantImmunogenMouse myeloma cell line NS0-derived recombinant human JAM-ASer28-Ala242 (predicted)Accession # Q9Y624FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.LabelUnconjugated Flow Cytometry0.25 µg/106 cellsSee belowImmunohistochemistry8-25 µg/mLSee below CyTOF-readyReady to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.Immunocytochemistry8-25 µg/mLSee belowReconstitutionSterile PBS to a final concentration of 0.5 mg/mL.ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °CStability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.6 months, -20 to -70 °C under sterile conditions after reconstitution. References:Chavakis, T. et al. (2003) Thromb. Haemost. 89:13.Aurand-Lions, M. et al. (2001) Blood 98:3699.Sobocka, M.B. et al. (2000) Blood 95:2600.Martin-Padura, I. et al. (1998) J. Cell Biol. 142:117.Williams, L.A. et. al. (1999) Mol. Immunol. 36:1175.Ostermann, G. et al. (2002) Nature Immunol. 3:151.Barton, E.S. et al. (2001) Cell 104:441.Long Name:Junctional Adhesion Molecule AEntrez Gene IDs:50848 (Human); 16456 (Mouse)Alternate Names:CD321 antigen; CD321; F11 receptor; F11R; JAM-1; JAM1CD321; JAMA; JAM-A; JCAMJAM; Junctional adhesion molecule 1Platelet F11 receptor; junctional adhesion molecule A; PAM-1; PAM-1KAT; Platelet adhesion molecule 1Background:The family of junctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial or epithelial cells. Some family members are also found on blood leukocytes and platelets. Human JAM-A, also known as platelet adhesion molecule 1 (PAM-1) and platelet F11 receptor (3), is predominantly expressed at intercellular junctions of both epithelial cells and endothelial cells (1 - 4). It is also expressed on circulating blood cells including neutrophils, monocytes, platelets, erythrocytes and lymphocytes (5). Human JAM-A cDNA predicts a 299 amino acid (aa) residue precursor protein with a putative 27 aa signal peptide, a 210 aa extracellular region containing two Ig-like V-subset domains, a 24 aa transmembrane domain and a 38 aa cytoplasmic domain. The human and mouse proteins share approximately 67% aa sequence homology. Human JAM-A also shares approximately 35% and 32% aa sequence homology with human JAM-B and JAM-C, respectively. JAM-A exhibits homophilic interactions to regulate tight junction assembly and modulate paracellular permeability. This homophilic interation also mediates platelet aggregation and adhesion to endothelial cells and may play a role in thrombosis (3). JAM-A binds heterotypically with thebeta 2 integrin lymphocyte function-associated antigen-1 (LFA-1). This JAM-A-LFA-1 interaction is involved in leukocyte adhesion and transmigration (6). JAM-A has also been shown to bind reovirus attachment protein sigma-1 to permit reovirus infection and signal virus-induced apoptosis (7).

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。